Spero Therapeutics, Inc.

GSK’s Blujepa (gepotidacin) is the first new mechanism of action to address uncomplicated urinary tract infections (uUTIs) in more than 30 years. The US Food and Drug Administration approved Blujepa o

Pharmaceutical companies have a variety of strategic options available to them to restock pipelines and ensure continued innovation. In terms of external innovation, in-licensing assets from other com

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals

GSK’s gepotidacin has been put on the regulatory fast track in the US, raising hopes that it could be the first in a new class of oral antibiotic treatment for uncomplicated urinary tract infections (